Clinical Benefits of 7 Years of Treatment with Omalizumab in Severe Uncontrolled Asthmatics

References

• Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59:469–478.
   PubMed Web of Science ®Google Scholar
• Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100:1139–1151.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101:1483–1492.
   PubMed Web of Science ®Google Scholar
• Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009; 64:1728–1736.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009; 103:1633–1642.
   PubMed Web of Science ®Google Scholar
• van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, Mauad T, Hiemstra PS, Sterk PJ, Rabe KF. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009; 64:72–80.
   PubMed Web of Science ®Google Scholar
• Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, Kunkel G, Suttorp N, Seybold J. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117:1493–1499.
   PubMed Web of Science ®Google Scholar
• Pace E, Ferraro M, Bruno A, Bousquet J, Gjomarkaj M. Anti-inflammatory effects of seven years treatment with Omalizumab in severe uncontrolled asthmatics. Allergy 2010; 65:1495–1466.
   PubMed Web of Science ®Google Scholar
• Nopp A, Johansson SGO, Ankerst J, Palmqvist M, Oman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment Nopp. Allergy 2007; 62:1175–1181.
   PubMed Web of Science ®Google Scholar
• Nopp A, Johansson SGO, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65:56–60.
   PubMed Web of Science ®Google Scholar
• Miller MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel SE. TENOR Study Group. J Allergy Clin Immunol 2005; 116:990–995.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309–316.
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005; 26:319–338.
   PubMed Web of Science ®Google Scholar
• Polosa R, Morjaria J. Immunomodulatory and biologic therapies for severe refractory asthma. Respir Med 2008; 102:1499–510.
   PubMed Web of Science ®Google Scholar
• Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, Bel E, Burney P, Chanez P, Connett G, Corrigan C, de Blic J, Fabbri L, Holgate ST, Ind P, Joos G, Kerstjens H, Leuenberger P, Lofdahl CG, McKenzie S, Magnussen H, Postma D, Saetta M, Salmeron S, Sterk P. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999; 13:1198–1208.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999; 341:1966–1973.
   PubMed Web of Science ®Google Scholar
• Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB. Omalizumab rapidly decreases nasal allergic response and FcRI on basophils. J Allergy Clin Immunol 2004; 113:297–302.
   PubMed Web of Science ®Google Scholar
• Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828–1834.
   PubMed Web of Science ®Google Scholar
• Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123:107–113.
   PubMed Web of Science ®Google Scholar
• Sykes A, Johnston SL. Etiology of asthma exacerbations. J Allergy Clin Immunol 2008; 122:685–688.
   PubMed Web of Science ®Google Scholar
• Newcomb DC, Peebles RS Jr. Bugs and asthma: a different disease? Proc Am Thorac Soc 2009; 6:266–271.
   PubMedGoogle Scholar
• FitzGerald JM, Gibson PG. Asthma exacerbation 4: prevention. Thorax 2006; 61:991–999.
   Web of Science ®Google Scholar
• Saini SS, MacGlashan DW, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, Bochner BS. Down-regulation of human basophil IgE and FCεRIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999; 162:5624–5630.
   PubMed Web of Science ®Google Scholar
• Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, Kunkel G, Suttorp N, Seybold J. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117:1493–1499.
   PubMed Web of Science ®Google Scholar
• Chiappara G, Chanez P, Bruno A, Pace E, Pompeo F, Bousquet J, Bonsignore G, Gjomarkaj M. Variable p-CREB expression depicts different asthma phenotypes. Allergy 2007; 62:787–794.
   PubMed Web of Science ®Google Scholar
• Shannon J, Ernst P, Yamauchi Y, Olivenstein R, Lemiere C, Foley S, Cicora L, Ludwig M, Hamid Q, Martin JG. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133:420–426.
   PubMed Web of Science ®Google Scholar
• Gagliardo R, Chanez P, Vignola AM, Bousquet J, Vachier I, Godard P, Bonsignore G, Demoly P, Mathieu M. Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma. Am J Respir Crit Care Med 2000; 162:7–13.
   PubMed Web of Science ®Google Scholar
• Fukakusa M, Bergeron C, Tulic MK, Fiset PO, Al Dewachi O, Laviolette M, Hamid Q, Chakir J. Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa. J Allergy Clin Immunol 2005;115(2):280–286.
   PubMed Web of Science ®Google Scholar
• Gagliardo R, La Grutta S, Chanez P, Profita M, Paternò A, Cibella F, Bousquet J, Viegi G, Gjomarkaj M. Non-invasive markers of airway inflammation and remodeling in childhood asthma. Pediatr Allergy Immunol 2009; 20:780–790.
   PubMed Web of Science ®Google Scholar